Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

pfizer italia s.r.l. - sunitinib (sunitinib malate) - capsules hard - 50mg

Canada - English - Health Canada

pfizer canada ulc - sunitinib (sunitinib malate) - capsule - 50mg - sunitinib (sunitinib malate) 50mg - antineoplastic agents

United States - English - NLM (National Library of Medicine)

avkare - sunitinib malate (unii: lvx8n1ut73) (sunitinib - unii:v99t50803m) - sunitinib malate capsules are indicated for the treatment of adult patients with gastrointestinal stromal tumor (gist) after disease progression on or intolerance to imatinib mesylate. sunitinib malate capsules are indicated for the treatment of adult patients with advanced renal cell carcinoma (rcc). sunitinib malate capsules are indicated for the adjuvant treatment of adult patients at high risk of recurrent rcc following nephrectomy. sunitinib malate capsules are indicated for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pnet) in adult patients with unresectable locally advanced or metastatic disease. none. risk summary based on animal reproduction studies and its mechanism of action, sunitinib malate can cause fetal harm when administered to a pregnant woman [see clinical pharmacology ( 12.1)] . there are no available data in pregnant women to inform a drug-associated risk. in animal developmental and reproductive toxicology studies, oral administratio

Malta - English - Medicines Authority

aqvida gmbh kaiser-wilhelm-str 89, 20355 hamburg, germany - sunitinib - hard capsule - sunitinib 25 mg - antineoplastic agents

Malta - English - Medicines Authority

aqvida gmbh kaiser-wilhelm-str 89, 20355 hamburg, germany - sunitinib - hard capsule - sunitinib 50 mg - antineoplastic agents

Malta - English - Medicines Authority

aqvida gmbh kaiser-wilhelm-str 89, 20355 hamburg, germany - sunitinib - hard capsule - sunitinib 12.5 mg - antineoplastic agents

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

pfizer (malaysia) sdn. bhd. - sunitinib malate -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

pfizer (malaysia) sdn. bhd. - sunitinib malate -

United States - English - NLM (National Library of Medicine)

u.s. pharmaceuticals - sunitinib malate (unii: lvx8n1ut73) (sunitinib - unii:v99t50803m) - sutent is indicated for the treatment of adult patients with gastrointestinal stromal tumor (gist) after disease progression on or intolerance to imatinib mesylate. sutent is indicated for the treatment of adult patients with advanced renal cell carcinoma (rcc). sutent is indicated for the adjuvant treatment of adult patients at high risk of recurrent rcc following nephrectomy. sutent is indicated for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pnet) in adult patients with unresectable locally advanced or metastatic disease. none. risk summary based on animal reproduction studies and its mechanism of action, sutent can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . there are no available data in pregnant women to inform a drug-associated risk. in animal developmental and reproductive toxicology studies, oral administration of sunitinib to pregnant rats and rabbits throughout organogenesis resulted in teratogenicity (embryolet

Malta - English - Medicines Authority

boston biopharma limited malta life sciences park, building 2, level 0, san gwann sgn 3000, malta - sunitinib - hard capsule - sunitinib 12.5 mg - antineoplastic agents